TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33839115
Drug: Indoor air
Normalized name: air
DrugBank: Medical air (DB09337)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indoor air quality measurements of volatile organic compounds (VOCs) and inorganic gaseous pollutants using passive samplers over 7 days.
Study: 38344045
Drug: Letrozole (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Letrozole (2.5 mg/day)
Study: 35968476
Drug: Isha yoga
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isha yoga practice (3 minutes daily)
Study: 35968476
Drug: Active comparator
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active comparator (15 minutes daily reading)
Study: 35968476
Drug: Placebo comparator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo comparator (15 minutes daily reading)
Study: 32818346
Drug: Dexamethasone intraocular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone intraocular suspension 9%
Study: 32818346
Drug: Topical prednisolone
Normalized name: prednisolone Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical prednisolone acetate 1%
Study: 35403793
Drug: Cotadutide (50‐300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cotadutide (50‐300 μg, once‐daily subcutaneous)
Study: 35091036
Drug: Intraosseous regional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraosseous regional administration (IORA) of 500 mg vancomycin
Study: 35842199
Drug: High-Dose Interferon-α2b
Normalized name: Interferon α-2b
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-Dose Interferon-α2b (HDI)
Study: 33449378
Drug: Functional Family
Approvals — FDA: no, EMA: no, PMDA: no
Description: Functional Family Therapy (FFT) in addition to Treatment-As-Usual (TAU)
Study: 34436521
Drug: Cisplatin (70
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin (70 mg/m2 on day 1) and Gemcitabine (1000 mg/m2 on days 1 and 8 of a 21-day cycle)
Study: 34436521
Drug: Cisplatin (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin (60 mg/m2 on day 1), Gemcitabine (875 mg/m2 on days 1 and 8), and Berzosertib (90 mg/m2 on days 2 and 9 of a 21-day cycle)
Study: 34030899
Drug: Cold pack
Normalized name: CVS Cold Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cold pack kept in the refrigerator applied to the area above the IV catheter before drug infusion
Study: 34030899
Drug: Routine drug
Normalized name: Peace Out Acne Hero Routine KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine drug infusion without cold application in the control group
Study: 32167976
Drug: Iloprost (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iloprost (20 μg) inhaled
Study: 32167976
Drug: Saline inhaled
Normalized name: Broncho Saline Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline inhaled (Control)
Study: 32913154
Drug: Intra-rectal xylocaine
Normalized name: Xylocaine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intra-rectal xylocaine gel (10 mls)
Study: 32124566
Drug: Basal diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basal diet supplemented with 0.3 g/kg SB
Study: 32124566
Drug: Basal diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basal diet supplemented with 0.6 g/kg SB
Study: 32124566
Drug: Basal diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basal diet supplemented with 1.2 g/kg SB
Study: 34475868
Drug: Planned treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Planned treatment interruption
Study: 33891472
Drug: Atezolizumab 1,200
Normalized name: atezolizumab 1,200 mg/20 mL (60 mg/mL) INTRAVEN VIAL (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atezolizumab 1,200 mg plus platinum-based chemotherapy (paclitaxel plus carboplatin) and bevacizumab 15 mg/kg
Study: 33891472
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus platinum-based chemotherapy (paclitaxel plus carboplatin) and bevacizumab 15 mg/kg
Study: 35768286
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate nasal spray (MFNS) plus levocabastine nasal spray
Study: 35768286
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate nasal spray (MFNS) plus placebo nasal spray
Study: 34446497
Drug: CytoSorb therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: CytoSorb therapy (continuous for at least 24 hours, adsorber device changed every 12 hours)
Study: 34446497
Drug: CytoSorb therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: CytoSorb therapy (continuous for at least 24 hours, adsorber device changed every 24 hours)
Study: 32386466
Drug: Group-based multimodal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group-based multimodal physical therapy
Study: 32386466
Drug: Primary-care physical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primary-care physical therapy
Study: 37528476
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy of Er:YAG and long-pulsed Nd:YAG lasers
Study: 37528476
Drug: Er:YAG laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Er:YAG laser therapy only
Study: 35141517
Drug: Topical ethyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical ethyl chloride spray (ECS)
Study: 35141517
Drug: Subcutaneous 1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous 1% lidocaine injection (LI)
Study: 34521664
Drug: Inhaled amikacin
Normalized name: amikacin Inhalation Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled amikacin (20 mg/kg daily for 3 days)
Study: 34521664
Drug: Inhaled placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled placebo (0.9% Sodium Chloride)
Study: 36094783
Drug: Quarter-dose combination
Normalized name: Quarter Mate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quarter-dose combination of amlodipine, telmisartan, and chlorthalidone
Study: 36094783
Drug: Half-dose combination
Normalized name: propranolol hydrochloride Extended Release Oral Capsule [Half-Betadur CR]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Half-dose combination of amlodipine, telmisartan, and chlorthalidone
Study: 36094783
Drug: Third-dose combination
Normalized name: Third-generation cephalosporins
Approvals — FDA: no, EMA: no, PMDA: no
Description: Third-dose combination of amlodipine, telmisartan, and chlorthalidone
Study: 33155348
Drug: Culturally Adapted
Normalized name: casein, emmental cultured
Approvals — FDA: no, EMA: no, PMDA: no
Description: Culturally Adapted Cognitive Behavioral Therapy Plus Problem Management (CA-CBT+)
Study: 35794487
Drug: Peloid therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peloid therapy and home exercise
Study: 35794487
Drug: Paraffin therapy
Normalized name: Paraffin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paraffin therapy and home exercise
Study: 33355078
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid administration at the beginning of RARP
Study: 35631257
Drug: Ferric sodium
Normalized name: Ferric sodium EDTA
DrugBank: Ferric sodium citrate (DB13771)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ferric sodium EDTA in combination with vitamin C, folic acid, copper gluconate, zinc gluconate, and selenomethionine (Group 2; N = 22)
Study: 35631257
Drug: Oral ferrous
Normalized name: ferrous fumarate Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ferrous sulfate (Group 1; N = 20)
Study: 35631257
Drug: Ferric liposomal
Normalized name: Ferric Oxide
DrugBank: Ferric oxide (DB11576)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ferric liposomal formulation (Group 3; N = 20)
Study: 35630079
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (continued target medical therapy only)
Study: 32089822
Drug: MVA-NP+M1 co-administered
Normalized name: Ceramide Np
DrugBank: Ceramide NP (DB14111)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MVA-NP+M1 co-administered with licensed inactivated quadrivalent influenza vaccine
Study: 33292022
Drug: PCSO‐524® (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCSO‐524® (600 mg/d)
Study: 33292022
Drug: ESPO‐572® (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: ESPO‐572® (600 mg/d)
Study: 35049070
Drug: Single-dose rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Single-dose rituximab (S-Rtx) 375 mg/m2
Study: 35049070
Drug: Low-dose rituximab
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose rituximab (LD-Rtx) 100 mg weekly for 4 weeks
Study: 35258579
Drug: Pulsed low-intensity
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsed low-intensity ultrasonography (PLIUS) for 48 weeks, self-administered for 20 minutes daily.
Study: 35258579
Drug: Sham ultrasonography
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham ultrasonography for 48 weeks, self-administered for 20 minutes daily.
Study: 32209068
Drug: Sham ultrasound
Normalized name: ULTRASOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham ultrasound therapy for 2 minutes
Study: 35049249
Drug: Curcuma longa
Normalized name: Curcuma Longa
DrugBank: Turmeric (DB14276)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcuma longa (curcumin) 200 mg
Study: 35049249
Drug: Mefenamic acid
Normalized name: Mefenamic Acid
DrugBank: Mefenamic acid (DB00784)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mefenamic acid (MA) 500 mg
Study: 32285710
Drug: Energy drink
Normalized name: Boost Energy Drink
Approvals — FDA: no, EMA: no, PMDA: no
Description: Energy drink (250 mL Red Bull)
Study: 33879118
Drug: 2-weekly mobile
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-weekly mobile phone calls
Study: 32900671
Drug: Internet-administered Cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-administered Cognitive Behavioral Therapy (ICBT) for 12 weeks
Study: 33789728
Drug: Fluralaner (Exzolt®;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluralaner (Exzolt®; 0.5 mg/kg body weight) administered twice, 7 days apart via drinking water.
Study: 33789728
Drug: Fluralaner treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluralaner treatment
Study: 33259933
Drug: Radical hemithoracic
Normalized name: Campsis radicans flower extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radical hemithoracic radiation therapy (RHR)
Study: 33259933
Drug: Palliative radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Palliative radiation therapy (PR)
Study: 32851572
Drug: Other anticoagulant
Normalized name: Ether
DrugBank: Diethyl ether (DB13598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other anticoagulant treatments
Study: 32198301
Drug: Method of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Method of administration (intravascular vs intracerebral)
Study: 35124654
Drug: Bryostatin treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bryostatin treatment
Study: 32406431
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Vitamin A (2000 IU d‐1) and D (400 IU d‐1)
Study: 32406431
Drug: Standard pulmonary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard pulmonary tuberculosis therapy alone
Study: 35944371
Drug: dTMS twice
Normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: dTMS twice a day during 2 weeks
Study: 35944371
Drug: dTMS twice
Normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: dTMS twice a day during 3 weeks
Study: 32725073
Drug: Liberal fluid
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liberal fluid therapy (1500 ml of lactated Ringer's)
Study: 32725073
Drug: Restrictive fluid
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Restrictive fluid therapy (250 ml of lactated Ringer's)
Study: 35440333
Drug: Evening primrose
Normalized name: EVENING PRIMROSE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evening primrose vaginal capsule (500 mg) used vaginally, with a second capsule administered two hours later.
Study: 34600602
Drug: Apalutamide 240
Normalized name: apalutamide 240 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apalutamide 240 mg once daily plus abiraterone acetate 1000 mg once daily and prednisone 5 mg twice daily
Study: 34791068
Drug: Fluorine‐18 fluorodeoxyglucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluorine‐18 fluorodeoxyglucose (18F‐FDG) PET-CT scanning (FDG‐PET) before tapering (baseline) and after maximal tapering.
Study: 32601973
Drug: 1200 mg
Normalized name: aspirin 1200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1200 mg NAC twice daily (high dose group)
Study: 32601973
Drug: 1200 mg
Normalized name: aspirin 1200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1200 mg NAC daily (low dose group)
Study: 32601973
Drug: 1200 mg
Normalized name: aspirin 1200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1200 mg NAC twice daily (high dose group) and 1200 mg NAC daily (low dose group)
Study: 33830898
Drug: Micro-fragmented adipose
Normalized name: human adipose preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micro-fragmented adipose tissue (MFAT) injections under ultrasound guidance
Study: 32818641
Drug: Bleaching gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bleaching gel activated with 915 nm diode laser (1.5 W)
Study: 32818641
Drug: Bleaching gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bleaching gel activated with 915 nm diode laser (2.5 W)
Study: 32818641
Drug: Bleaching gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bleaching gel activated with 445 nm diode laser (1 W)
Study: 32818641
Drug: Bleaching gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bleaching gel activated with 445 nm diode laser (1.5 W)
Study: 32818641
Drug: Bleaching gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bleaching gel without laser activation (control group)
Study: 38856224
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg tirzepatide
Study: 38856224
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg tirzepatide
Study: 38856224
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg tirzepatide
Study: 35778473
Drug: Antibody-immobilized ELISAs
Normalized name: digoxin antibodies Fab fragments
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibody-immobilized ELISAs
Study: 34503985
Drug: Navafenterol 600
Normalized name: Navafenterol
DrugBank: Navafenterol (DB19195)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Navafenterol 600 µg via inhalation
Study: 34503985
Drug: Umeclidinium/vilanterol (UMEC/VI)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Umeclidinium/vilanterol (UMEC/VI) 62.5 µg/25 µg
Study: 32977348
Drug: Pharmacotherapy (placebo-controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacotherapy (placebo-controlled trial)
Study: 32977348
Drug: Routine airway
Normalized name: inBreath airway transplant system
DrugBank: inBreath airway transplant system (DB18692)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine airway clearance and treatment of recurrent respiratory tract infections
Study: 32977348
Drug: Organ-specific treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Organ-specific treatment for non-respiratory symptoms
Study: 32127889
Drug: Intra-operative low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intra-operative low-dose ketamine (0.15mg/kg bolus at induction and continuous infusion of 0.12 mg/kg/hour till start of skin closure)
Study: 32127889
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups received Morphine 0.1 mg/kg IV at debulking
Study: 33315503
Drug: Fat graft
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fat graft injections
Study: 33315503
Drug: Nanofat-enriched fat
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nanofat-enriched fat graft injections
Study: 32447857
Drug: Acupuncture plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture plus hyperbaric oxygen (HBO) therapy
Study: 32447857
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (simple HBO therapy)
Study: 36056784
Drug: Intralesional purified
Normalized name: RAYON,PURIFIED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralesional purified protein derivative (PPD) injected at a dose of 0.1 ml every 2 weeks until complete improvement or for a maximum of four sessions.
Study: 36056784
Drug: Intralesional Candida
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralesional Candida antigen (CA) injected at a dose of 0.1 ml every 2 weeks until complete improvement or for a maximum of four sessions.
Study: 36155998
Drug: Radiofrequency ozone
Normalized name: ozone
DrugBank: Ozone (DB12510)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiofrequency ozone therapy
Study: 36155998
Drug: Injection of
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of anti‐inflammatory analgesic solution into the internal orifice of nerve root
Study: 36155998
Drug: Traditional Chinese
Normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Chinese medicine hook operation (in addition to basic group treatment)
Study: 34036813
Drug: Electroacupuncture plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electroacupuncture plus auricular acupressure treatment twice weekly for 6 weeks
Study: 34036813
Drug: Electroacupuncture plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electroacupuncture plus auricular acupressure treatment
Study: 33175623
Drug: Nanocolloidal silver-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nanocolloidal silver-based gel (SilvoGel)
Study: 35587267
Drug: Selegiline (commercial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selegiline (commercial inhibitor of MAO-B)
Study: 34247040
Drug: Wine group
Normalized name: Wine grape
DrugBank: Wine grape (DB10634)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wine group (27 g of alcohol per day)
Study: 34247040
Drug: Ethanol group
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ethanol group (27 g of alcohol per day)
Study: 34997314
Drug: Intravenous placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous placebo + oral cetirizine 10 mg
Study: 34997314
Drug: Intravenous diphenhydramine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous diphenhydramine 50 mg + oral placebo
Study: 34318757
Drug: Standard-dose CT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose CT (120 kV and 300 mA)
Study: 34318757
Drug: Low-dose CT
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose CT (80 kV and 40 mA)
Study: 32170307
Drug: CBT-I concurrent
Normalized name: iobenguane I-131
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBT-I concurrent with PAP
Study: 38578537
Drug: Bevacizumab-containing chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab-containing chemotherapy
Study: 32283195
Drug: Oleogel-dissolved CoQ10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oleogel-dissolved CoQ10 (1 g CoQ10/5 g oleogel-disk)
Study: 32283195
Drug: Oleogel-dissolved CoQ10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oleogel-dissolved CoQ10 (repeated-dose for 14 days)
Study: 36346322
Drug: Spectrum Red
Normalized name: acid red 35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spectrum Red (2.5 mg THC, 0.3 mg CBD/softgel)
Study: 36346322
Drug: Spectrum Yellow
Normalized name: yellow OB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spectrum Yellow (0.9 mg THC, 20 mg CBD/mL of oil)
Study: 33572499
Drug: HIIT (High-Intensity
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIIT (High-Intensity Interval Training) - 6 weeks, 12 bouts first 2 weeks, 16 bouts in weeks 3 and 4, and 20 bouts in the last two weeks x 30‐s intervals interspersed with 1‐min rest periods, performed thrice weekly
Study: 32318695
Drug: Allopurinol 600
Normalized name: Allopurinol
DrugBank: Allopurinol (DB00437)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Allopurinol 600 mg once daily for 20 weeks
Study: 33248975
Drug: 5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/kg intravenous tranexamic acid
Study: 33248975
Drug: 10 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/kg intravenous tranexamic acid
Study: 33248975
Drug: 15 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg/kg intravenous tranexamic acid
Study: 35414602
Drug: Intensive glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive glucose treatment (serum glucose <110 mg/dL)
Study: 35414602
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (serum glucose <180 mg/dL)
Study: 32429680
Drug: Pharmacological treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacological treatment (diclofenac sodium)
Study: 32429680
Drug: Electroacupuncture (EA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electroacupuncture (EA) and pharmacological treatment (diclofenac sodium)
Study: 34358953
Drug: High g1
Normalized name: HIGH DENSITY POLYETHYLENE
Approvals — FDA: no, EMA: no, PMDA: no
Description: High g1 treatment
Study: 34358953
Drug: Standard g1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard g1 treatment
Study: 33067280
Drug: Initiation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initiation of mental healthcare (psychometric testing by GP, talk therapy by GP, contact with a psychologist, contact with a psychiatrist, psychotropic medication)
Study: 34206058
Drug: Hepatitis B
Normalized name: HEPATITIS B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatitis B birth dose vaccine (HepB‐BD) administered to infants in addition to routine vaccines (0-8-12-16 weeks) during the intervention period.
Study: 34142748
Drug: Transdiagnostic cognitive-behavior
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdiagnostic cognitive-behavior therapy (tCBT)